Clinical Trials Logo

Clinical Trial Summary

A Research Study to evaluate the therapeutic effect of Fespixon cream in patients suffering from DFU (UTWCS Grade III-A or III-B) by measuring the change of grade of UTWCS (University of Texas Diabetic Wound Classification system), wound area reduction, infection control, and incidence of treatment-emergent adverse event (TEAE).


Clinical Trial Description

This study is designed as a single-arm, open-label, one-center study to evaluate the therapeutic effect of Fespixon cream in patients suffering from DFU (UTWCS Grade III-A or III-B). The duration of this study is: run-in/ screening phase (7 days ± 3 days); treatment phase (12 weeks); follow-up phase (2 weeks ± 4 days), and visits are conducted every week during the run-in/ screening phase and every 2 weeks during the treatment phase and follow-up phase for a total of 9 visits. During the treatment phase, the Fespixon cream will be applied to the target ulcer twice a day for a maximum period of 12 weeks, until the target ulcer downgrade from UTWCS grade III-A or III-B to I-A, I-B, II-A, or II-B for two consecutive visits at least 2 weeks apart, or until the subject exited the study as treatment failure. After that, all subjects regardless of wound grade-down at the end of the treatment phase will be followed for 2 weeks. During the follow-up phase, standard of care or other treatment modalities (with an exception of investigational treatment/ medications) will be used for all subjects at the discretion of the investigator. At each visit, the size and changes of the target ulcer are recorded by photographing. The target ulcer area in the photo is calculated using Image-Pro® Plus software. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05438251
Study type Interventional
Source Oneness Biotech Co., Ltd.
Contact
Status Terminated
Phase Phase 4
Start date August 4, 2022
Completion date April 3, 2024

See also
  Status Clinical Trial Phase
Completed NCT04277598 - A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer Phase 1/Phase 2
Not yet recruiting NCT06449638 - Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs N/A
Completed NCT04372355 - Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients Phase 2
Completed NCT01912092 - Askina Calgitrol Paste Diabetic Foot Ulcers N/A